Incidence, Outcomes and Risk Factors for Atrial Fibrillation in Patients With JAK2 V617F ‐Positive Myeloproliferative Neoplasms
Authors:
Open Access
- 3 July 2025
- journal article
- Published by Wiley in Cancer Medicine
- Vol. 14 (13)
Abstract
Background: The incidence, outcomes and risk factors for AF in the JAK2 V617F ‐positive MPN patients are still unknown. Methods: The clinical profiles of patients with JAK2 V617F ‐positive MPN were retrospectively analyzed. Multivariable Cox regression analysis was performed to identify risk factors of AF, thereby developing a risk prediction model. Results: A total of 439 patients were included (age 57 [12–87] years; 51.3% male). AF was associated with higher risks of stroke ( p = 0.036, HR = 1.987, 95% CI 1.047–3.772) and mortality ( p < 0.001, HR = 3.857, 95% CI 1.836–8.103). Multivariable Cox regression showed that TET2 mutation ( p = 0.042, HR = 4.361, 95% CI 1.053–18.056) and increased IL‐1β ( p = 0.012, HR = 5.476, 95% CI 1.547–28.123) were significant risk factors for AF in patients with JAK2 V617F ‐positive MPN. Nomograms were constructed, allowing patients to be categorized into high‐ and low‐risk groups. The 10‐year AF‐free survival rate was significantly lower in the high‐risk group (62% vs. 91.7%; log‐rank test: p = 0.002). The validation cohort confirmed that the survival without AF in the high‐risk group was significantly worse than that in the low‐risk group. The use of either interferon‐α or ruxolitinib, was associated with longer AF‐free survival in the high‐risk group ( p < 0.05). Conclusion: AF was significantly associated with higher risks of stroke and mortality. TET2 mutation and increased IL‐1β were independent risk factors of AF in patients with JAK2 V617F ‐positive MPN.Keywords
Funding Information
- National Natural Science Foundation of China (82270148)
This publication has 31 references indexed in Scilit:
- B‐cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon‐α2, or combination treatmentEuropean Journal of Haematology, 2019
- Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-AnalysisCardiology Research and Practice, 2019
- Enhanced Cardiomyocyte NLRP3 Inflammasome Signaling Promotes Atrial FibrillationCirculation, 2018
- Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 InflammasomeJACC, 2018
- Overview of the IL‐1 family in innate inflammation and acquired immunityImmunological Reviews, 2017
- Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in miceScience, 2017
- Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort studyClinical Epidemiology, 2017
- Plasma cytokines in polycythemia vera: Phenotypic correlates, prognostic relevance, and comparison with myelofibrosisAmerican Journal of Hematology, 2012
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling StudyJournal of Clinical Oncology, 2011
- Interleukin-1 (IL-1) PathwayScience Signaling, 2010